Literature DB >> 11720695

Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults.

T J Fabian1, M A Dew, B G Pollock, C F Reynolds, B H Mulsant, M A Butters, M D Zmuda, A M Linares, M Trottini, P D Kroboth.   

Abstract

BACKGROUND: Clinical studies of endogenous concentrations of dehydroepiandrosterone (DHEA) and its sulfated conjugate DHEA-S in depression are limited. This study was designed to evaluate the influence of successful pharmacological treatment of late-life depression on concentrations of DHEA, DHEA-S and cortisol.
METHODS: We determined endogenous concentrations of DHEA, DHEA-S and cortisol in elderly control subjects (n = 16) and in elderly depressed patients who remitted (n = 44) or failed to remit (n = 16) with pharmacological treatment. Depressed patients were treated for 12 weeks with either nortriptyline or paroxetine.
RESULTS: In remitters, DHEA and DHEA-S concentrations were lower at week 12 than at week 0 (p =.002 and p =.0001, respectively). In the nonremitters and control subjects, neither DHEA nor DHEA-S concentrations changed. Decreases in hormone concentrations were associated with improvement in mood and functioning in depressed patients. Although cortisol concentrations decreased in remitters and nonremitters, the change was not significant.
CONCLUSIONS: Our data suggest that the decrease in DHEA and DHEA-S in remitters is related to remission of depression rather than to a direct drug effect on steroids, as nonremitters had no change in hormone concentrations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720695     DOI: 10.1016/s0006-3223(01)01198-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN).

Authors:  Joyce T Bromberger; Laura L Schott; Howard M Kravitz; Maryfran Sowers; Nancy E Avis; Ellen B Gold; John F Randolph; Karen A Matthews
Journal:  Arch Gen Psychiatry       Date:  2010-06

Review 2.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 3.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

4.  Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men.

Authors:  Elizabeth C Prom-Wormley; Timothy P York; Kristen C Jacobson; Lindon J Eaves; Sally P Mendoza; Dirk Hellhammer; Nicole Maninger; Seymour Levine; Sonia Lupien; Michael J Lyons; Richard Hauger; Hong Xian; Carol E Franz; William S Kremen
Journal:  Psychoneuroendocrinology       Date:  2011-05-12       Impact factor: 4.905

5.  Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone.

Authors:  Yusuke Miwa; Airi Nishimi; Shinichiro Nishimi; Mayu Saito; Takahiro Tokunaga; Ryo Yanai; Ryo Takahashi; Kuninobu Wakabayashi; Tsuyoshi Kasama; Michio Hosaka
Journal:  Eur J Rheumatol       Date:  2014-12-01

6.  Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.

Authors:  Daniela Eser; Cornelius Schüle; Elena Romeo; Thomas C Baghai; Flavia di Michele; Augusto Pasini; Peter Zwanzger; Frank Padberg; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

7.  Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression.

Authors:  Christina M Hough; Daniel Lindqvist; Elissa S Epel; Molly St Denis; Victor I Reus; F Saverio Bersani; Rebecca Rosser; Laura Mahan; Heather M Burke; Owen M Wolkowitz; Synthia H Mellon
Journal:  Psychoneuroendocrinology       Date:  2016-12-05       Impact factor: 4.905

8.  Dysregulation of neurosteroids in obsessive compulsive disorder.

Authors:  K L Bigos; M M Folan; M R Jones; G L Haas; F J Kroboth; P D Kroboth
Journal:  J Psychiatr Res       Date:  2008-06-02       Impact factor: 4.791

9.  Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis.

Authors:  Felipe A Jain; Colm G Connolly; Victor I Reus; Dieter J Meyerhoff; Tony T Yang; Synthia H Mellon; Scott Mackin; Christina M Hough; Alexandra Morford; Owen M Wolkowitz
Journal:  Psychoneuroendocrinology       Date:  2019-07-26       Impact factor: 4.905

10.  Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women.

Authors:  Melinda L Morgan; Andrea J Rapkin; Giovanni Biggio; Mariangela Serra; Maria Giuseppina Pisu; Natalie Rasgon
Journal:  Arch Womens Ment Health       Date:  2009-09-03       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.